期刊文献+

噻吩和三唑酮类Chk1抑制剂的特征结构研究 被引量:2

Study on the Structural Features of Thiophenes and Triazolones as Chk1 Inhibitors
原文传递
导出
摘要 检验点激酶1(Chk1)是一种丝氨酸/苏氨酸蛋白激酶,可使受损癌细胞发生细胞周期阻滞并促进DNA损伤修复,降低放疗对肿瘤细胞的杀伤作用。抑制Chk1活性可消除细胞周期阻滞,阻碍肿瘤细胞的自我修复,导致其有丝分裂紊乱最终凋亡。本文采用多元线性回归(MLR)和主成分回归分析(PCA)方法,对164个噻吩和三唑酮类Chk1抑制剂分子的698个参数进行回归分析,分别建立定量构效关系预测模型。结果表明,多元线性回归中的逐步回归(stepwise)是最佳建模方法,所建模型的预测能力较强(训练集R=0.85,检验集R=0.88),运用拓扑电荷指数、原子核片段等20个参数直观反映了影响活性的主要因素。此模型的确立对设计和开发新型高效Chk1抑制剂具有指导意义。 Checkpoint kinasel (Chk1), a serine/threonine protein kinase, mediates the cellular response to DNA-damage by leading to cell-cycle arrest, and reduces the therapeutic efficacy of radiotherapy. Inhibition of Chkl has been shown to abrogate DNA damage induced cell cycle arrest, impeding cancer cells to repair themselves and leading to mitotic catastrophe and cell death or apoptosis. In this paper, 698 molecular indices, coming from 164 thiophenes and triazolones as Chkl inhibitors, were regressed by using multiple linear regression (MLR) and principal component regression analysis (PCA) methods, finally ending up with the optimum predictable models. The results showed that stepwise regression analysis was the best regression method. The developed model showed its proper predictability by the independent training set (R = 0.85 ) and test set ( R = 0.88 ) , employing 20 molecular indices, such as topological charge indices, atom-centred fragments, directly reflecting the main factors influencing activity of the inhibitors. This model is helpful for the design and development of new, efficient Chkl inhihitors.
出处 《化学通报》 CAS CSCD 北大核心 2014年第1期71-76,共6页 Chemistry
基金 国家自然科学基金项目(21103129) 山东省科技发展计划项目(2012YD17007) 潍坊市科技发展计划项目(20121299)资助
关键词 Chk1抑制剂 定量构效关系 多元线性回归 主成分分析 Chk1 inhihitors, QSAR, Multiple linear regression, Principle component regression analysis
  • 相关文献

参考文献20

二级参考文献28

  • 1Zhou B B, Elledge S J. The DNA damage response: Putting checkpoints in perspective. Nature, 2000, 408:433-439. 被引量:1
  • 2Zachos G, Rainey M D, Gillespie D A. Chkl-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J, 2003, 22:713-723. 被引量:1
  • 3Merry C, Fu K, Wang J, et al. Targeting the checkpoint kinase Chkl in cancer therapy. Cell Cycle, 2010, 9:279-283. 被引量:1
  • 4Ng C P, Lee H C, Ho C W, et al. Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem, 2004, 279:8808-8819. 被引量:1
  • 5Sweeney G. Leptin signalling. Cell Signal, 2002, 14:655-663. 被引量:1
  • 6Bolderson E, Richard D J, Zhou B B, et al. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res, 2009, 15:6314-6320. 被引量:1
  • 7Carrassa L, Sanchez Y, Erba E, et al. U2OS cells lacking Chkl undergo aberrant mitosis and fail to activate the spindle check-point. J Cell Mol Med, 2009, 13:1565-1576. 被引量:1
  • 8Karlsson-Rosenthal C, Millar J B. Cdc25: Mechanisms of checkpoint inhibition and recovery. Trends Cell Biol, 2006, 16:285-292. 被引量:1
  • 9Pan Y, Ren K H, He H W, et al. Knockdown of Chkl sensitizes human colon carcinoma HCTll6 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis. Cancer Biol Ther, 2009, 8:1559-1566. 被引量:1
  • 10McNeely S, Conti C, Sheikh T, et al. Cbk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle, 2010, 9:995-1004. 被引量:1

同被引文献9

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部